Business Context and Reporting Period
This Form 8-K reports on events occurring at the 2025 Annual Meeting of Stockholders for Agios Pharmaceuticals, Inc., held on June 18, 2025. The filing details corporate governance actions, including the election of directors, executive compensation votes, and amendments to equity incentive plans.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing the number of shares available for issuance by 2,500,000. This increase applies to both the total shares available and the specific allotment for incentive stock options.
- Director Elections: Stockholders elected Jacqualyn A. Fouse, Ph.D. and David Scadden, M.D. as Class III directors for three-year terms expiring in 2028.
- Executive Compensation: Stockholders approved the non-binding advisory vote on executive compensation.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm.
Voting Results Summary
| Matter | Votes For | Votes Against/Withheld | Abstentions |
|---|---|---|---|
| Election of Jacqualyn A. Fouse, Ph.D. | 45,959,402 | 3,925,859 (Withheld) | N/A |
| Election of David Scadden, M.D. | 46,204,689 | 3,680,572 (Withheld) | N/A |
| Executive Compensation (Say-on-Pay) | 46,843,926 | 3,024,905 | 16,430 |
| 2023 Plan Amendment | 31,683,420 | 18,197,324 | 4,517 |
| Ratification of Auditor | 51,200,808 | 136,734 | 22,781 |
Guidance, Outlook, and Risks
This filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies. The document focuses strictly on the results of the stockholder vote and the formal adoption of the equity plan amendment.
Investor Verification Checklist
- Verify the impact of the 2,500,000 share increase on potential future dilution by reviewing the full text of the amended 2023 Stock Incentive Plan (Exhibit 99.1).
- Note the significant number of votes against the 2023 Plan Amendment (18,197,324), which represents a substantial minority of the voting shares, indicating potential shareholder concern regarding equity dilution.
- Confirm the tenure of the newly elected directors (Fouse and Scadden) extends through the 2028 Annual Meeting.
- Review the definitive proxy statement filed on April 25, 2025, for detailed terms of the equity plan and director biographies.